[go: up one dir, main page]

FR09C0011I2 - - Google Patents

Info

Publication number
FR09C0011I2
FR09C0011I2 FR09C0011C FR09C0011C FR09C0011I2 FR 09C0011 I2 FR09C0011 I2 FR 09C0011I2 FR 09C0011 C FR09C0011 C FR 09C0011C FR 09C0011 C FR09C0011 C FR 09C0011C FR 09C0011 I2 FR09C0011 I2 FR 09C0011I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR09C0011C
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26736901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR09C0011(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR09C0011I1 publication Critical patent/FR09C0011I1/fr
Application granted granted Critical
Publication of FR09C0011I2 publication Critical patent/FR09C0011I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR09C0011C 1997-08-28 2009-03-12 Active FR09C0011I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6983797P 1997-08-28 1997-08-28
US5780397P 1997-08-28 1997-08-28
PCT/EP1998/005414 WO1999011605A1 (fr) 1997-08-28 1998-08-26 Certains acides 5-alkyl-2-arylaminophenylacetiques et leurs derives

Publications (2)

Publication Number Publication Date
FR09C0011I1 FR09C0011I1 (fr) 2009-04-17
FR09C0011I2 true FR09C0011I2 (fr) 2011-04-01

Family

ID=26736901

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0011C Active FR09C0011I2 (fr) 1997-08-28 2009-03-12

Country Status (35)

Country Link
US (5) US6291523B1 (fr)
EP (1) EP1007505B1 (fr)
JP (1) JP3704470B2 (fr)
KR (1) KR100637296B1 (fr)
CN (1) CN1140500C (fr)
AR (1) AR015157A1 (fr)
AT (1) ATE237580T1 (fr)
AU (1) AU743371B2 (fr)
BR (1) BR9812010B1 (fr)
CA (1) CA2298033C (fr)
CO (1) CO4960662A1 (fr)
CY (1) CY2007020I2 (fr)
CZ (1) CZ298522B6 (fr)
DE (4) DE69813570T2 (fr)
DK (1) DK1007505T3 (fr)
ES (1) ES2197508T3 (fr)
FR (1) FR09C0011I2 (fr)
HK (1) HK1031374A1 (fr)
HU (1) HU225774B1 (fr)
ID (1) ID23953A (fr)
IL (2) IL134498A0 (fr)
LU (2) LU91346I2 (fr)
MY (1) MY127881A (fr)
NL (1) NL300379I2 (fr)
NO (2) NO326196B1 (fr)
NZ (1) NZ502669A (fr)
PE (1) PE108099A1 (fr)
PL (1) PL194480B1 (fr)
PT (1) PT1007505E (fr)
RU (1) RU2186762C2 (fr)
SI (1) SI1007505T1 (fr)
SK (1) SK283773B6 (fr)
TR (1) TR200000447T2 (fr)
TW (1) TWI250142B (fr)
WO (1) WO1999011605A1 (fr)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ES2234324T3 (es) * 1998-11-02 2005-06-16 MERCK & CO., INC. Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña.
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
GB9922830D0 (en) * 1999-09-27 1999-11-24 Novartis Ag Processes
SK12672001A3 (sk) 1999-12-08 2002-04-04 Pharmacia Corporation Zloženia inhibítora cyklooxygenázy-2 s rýchlym nástupom terapeutického účinku
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
AU2001216038A1 (en) * 2000-11-14 2002-05-27 Alcon Laboratories Inc. Treatment of glaucoma and ocular hypertension
US20050264906A1 (en) * 2004-05-25 2005-12-01 Haratsch Erich F Method and apparatus for reduced-state Viterbi detection in a read channel of a magnetic recording system
US7656959B2 (en) 2001-04-13 2010-02-02 Agere Systems Inc. Pipelined decision-feedback unit in a reduced-state viterbi detector with local feedback
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
WO2003022815A1 (fr) 2001-09-10 2003-03-20 Sugen, Inc. Derives de 3-(4,5,6,7-tetrahydroindol-2-ylmethylidene)-2-indolinone comme inhibiteurs de kinases
EP1434576A4 (fr) 2001-09-13 2006-03-29 Kenneth E Miller Methode pour soulager la douleur
US7504231B2 (en) * 2001-09-13 2009-03-17 The Board Of Regents Of The University Of Oklahoma Method of alleviating chronic pain via peripheral inhibition of neurotransmitter synthesis
GB0124459D0 (en) * 2001-10-11 2001-12-05 Novartis Ag Organic compounds
JP2005506366A (ja) * 2001-10-25 2005-03-03 ノバルティス アクチエンゲゼルシャフト 選択的シクロオキシゲナーゼ−２阻害剤を含む組合せ剤
HUP0402370A3 (en) * 2001-11-06 2008-04-28 Novartis Ag Pharmaceutical compositions containing cyclooxigenase-2 inhibitor and histone deacetylase inhibitor combination
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
BR0308156A (pt) * 2002-03-07 2005-01-04 Novartis Ag Composições farmacêuticas sólidas contendo lumiracoxib
GB0209257D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
CA2487414A1 (fr) 2002-06-11 2003-12-18 Nitromed, Inc. Inhibiteurs selectifs de cyclooxigenase-2 nitroses et/ou nitrosyles, compositions et methodes d'utilisation
ITMI20021391A1 (it) 2002-06-25 2003-12-29 Nicox Sa Nitroderivati di inibitori della cicloossigenasi-2
WO2004009056A1 (fr) 2002-07-23 2004-01-29 Novartis Ag Composition d'onguent ophtalmique comprenant un medicament, une base d'onguent et un agent de solubilisation/dispersion
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
AU2003294221A1 (en) * 2002-09-13 2004-04-19 Kenneth E. Miller Method of alleviating pain via inhibition of neurotransmitter synthesis
GB0224198D0 (en) * 2002-10-17 2002-11-27 Novartis Ag Organic compounds
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
AR042206A1 (es) * 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
BR0317384A (pt) * 2002-12-18 2005-11-16 Novartis Ag Combinações de valsartan com inibidores de cox-2
US7157577B2 (en) 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
TWI327913B (en) * 2003-03-12 2010-08-01 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US20040229803A1 (en) * 2003-04-22 2004-11-18 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
US20040220187A1 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
US20060135506A1 (en) * 2003-04-22 2006-06-22 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
US20050159403A1 (en) * 2003-04-22 2005-07-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage
EP1745791B1 (fr) 2003-05-07 2013-06-26 Osteologix A/S Sels de strontium hydrosolubles pour le traitement d'affections de cartilage et/ou d'os
WO2004100895A2 (fr) * 2003-05-13 2004-11-25 Pharmacia Corporation Compositions comprenant un inhibiteur selectif de la cyclooxygenase-2 et un agoniste des recepteurs actives par les proliferateurs de peroxysomes, pour traiter des troubles d'origine ischemique du systeme nerveux central
US20050026919A1 (en) * 2003-05-14 2005-02-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20060160776A1 (en) * 2003-05-28 2006-07-20 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
WO2005007106A2 (fr) * 2003-07-10 2005-01-27 Pharmacia Corporation Compositions renfermant un inhibiteur selectif de la cyclooxygenase 2 et un modulateur du glutamate non-nmda pour le traitement d'une lesion du systeme nerveux central
US20050014729A1 (en) * 2003-07-16 2005-01-20 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
WO2005009354A2 (fr) * 2003-07-17 2005-02-03 Pharmacia Corporation Compositions contenant un inhibiteur selectif de la cyclooxygenase-2 et un inhibiteur des ikk, utilisees dans le traitement des troubles ou lesions d'origine ischemique du systeme nerveux central
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
US20050130971A1 (en) * 2003-08-22 2005-06-16 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
WO2005023189A2 (fr) * 2003-09-03 2005-03-17 Pharmacia Corporation Procede de prevention ou de traitement de la douleur, de l'inflammation, et de troubles lies a l'inflammation avec un inhibiteur selectif de cox-2 en combinaison avec un agent donneur de monoxyde d'azote et compositions en contenant
CA2540623A1 (fr) * 2003-10-03 2005-04-28 Pharmacia Corporation Compositions a base d'inhibiteur selectif de la cyclooxygenase-2 administrees dans des conditions d'hypothermie pour le traitement de lesions ou de troubles du systeme nerveux central induits par une ischemie
CN1897929A (zh) * 2003-10-08 2007-01-17 诺瓦提斯公司 包含5－甲基－2－(2′－氯－6′－氟苯胺基)苯乙酸的药物组合物
BRPI0415939A (pt) * 2003-11-12 2007-01-02 Pharmacia & Upjohn Co Llc composições de um inibidor seletivo da ciclooxigenase-2 e um agente de modulação do fator neurotrófico para o tratamento de distúrbios mediados pelo sistema nervoso central
JP4792294B2 (ja) 2004-01-07 2011-10-12 生化学工業株式会社 ヒアルロン酸誘導体及びそれを含む薬剤
WO2005089718A2 (fr) 2004-03-23 2005-09-29 Novartis Ag Compositions pharmaceutiques
TW200603792A (en) * 2004-04-23 2006-02-01 Pharmacia & Upjohn Co Llc Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
US7487432B2 (en) * 2004-05-25 2009-02-03 Agere Systems Inc. Method and apparatus for multiple step Viterbi detection with local feedback
US7653154B2 (en) * 2004-05-25 2010-01-26 Agere Systems Inc. Method and apparatus for precomputation and pipelined selection of intersymbol interference estimates in a reduced-state Viterbi detector
US7380199B2 (en) * 2004-05-25 2008-05-27 Agere Systems Inc. Method and apparatus for precomputation and pipelined selection of branch metrics in a reduced-state Viterbi detector
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0416508D0 (en) * 2004-07-23 2004-08-25 Merck Sharp & Dohme Therapeutic agents
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
DE102004044827A1 (de) * 2004-09-16 2006-03-23 Bayer Cropscience Ag Jod-phenylsubstituierte cyclische Ketoenole
SI1817282T1 (sl) 2004-11-23 2011-10-28 Astrazeneca Ab Derivati fenoksiocetne kisline, uporabni za zdravljenje respiratornih bolezni
EP1833795B1 (fr) 2004-12-23 2009-03-04 Glaxo Group Limited Composes de pyridine destines au traitement de maladies a mediation par prostaglandine
CA2598645A1 (fr) * 2005-02-22 2006-08-31 Merial Limited Methodes de traitement selectif de troubles induits par cox-2 par administration de gamma-tocopherol
AP2552A (en) 2005-04-26 2013-01-08 Pfizer P-cadherin antibodies
US20060251702A1 (en) * 2005-05-05 2006-11-09 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
TWI453218B (zh) 2005-09-07 2014-09-21 Amgen Fremont Inc 針對類活化素受體激酶－１之人類單株抗體
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007039736A1 (fr) 2005-10-06 2007-04-12 Astrazeneca Ab Nouveaux composes
JP2007275193A (ja) * 2006-04-04 2007-10-25 Fujifilm Corp 光プローブおよび光断層画像化装置
AR061623A1 (es) 2006-06-26 2008-09-10 Novartis Ag Derivados de acido fenilacetico
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
US7943658B2 (en) * 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2203411B1 (fr) 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. Dérivés de l'acide n-phénylanthranilique et leurs utilisations
US20090082452A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lumiracoxib
US8067445B2 (en) 2008-02-01 2011-11-29 Panmira Pharmaceuticals, Llc N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
EP2257536A4 (fr) 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc Composés diaryliques cycliques en tant qu'antagonistes de récepteurs de prostaglandine d2
WO2009108720A2 (fr) 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonistes des récepteurs d2 de la prostaglandine
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US20110190227A1 (en) 2008-07-03 2011-08-04 Amira Pharmaceuticals, Inc. Antagonists of Prostaglandin D2 Receptors
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (fr) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Antagonistes hétéroalkyl biphényle des récepteurs de la prostaglandine d2
EP2177215A1 (fr) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-cristaux de tramadol et NSAID
US8227451B2 (en) * 2008-11-12 2012-07-24 Auspex Pharmaceuticals Phenylacetic acid inhibitors of cyclooxygenase
WO2010057118A2 (fr) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
WO2011012622A1 (fr) 2009-07-30 2011-02-03 Glaxo Group Limited Dérivés de benzoxazinone pour traiter des troubles induits par glytl
KR20120038544A (ko) 2009-07-31 2012-04-23 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 수용체 길항제의 안과용 약학 조성물
JP2013501052A (ja) 2009-08-05 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２アンタゴニストおよびその用途
WO2011023753A1 (fr) 2009-08-27 2011-03-03 Glaxo Group Limited Dérivés de benzoxazine inhibiteurs du transport de glycine
EA201270653A1 (ru) 2010-01-06 2012-11-30 ПАНМИРА ФАРМАСЬЮТИКАЛС, ЭлЭлСи Антагонист dpи его применение
GB201000685D0 (en) 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
GB201007789D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel Compound
GB201007791D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel compounds
EP2590953B1 (fr) 2010-07-09 2014-10-29 Convergence Pharmaceuticals Limited Dérivés de tétrazole comme bloqueurs des canaux calciques
US8892989B1 (en) * 2010-08-26 2014-11-18 Clearslide, Inc. Method for searching companies and people
US8900798B2 (en) 2010-10-18 2014-12-02 Eastman Kodak Company On-press developable lithographic printing plate precursors
US20120090486A1 (en) 2010-10-18 2012-04-19 Celin Savariar-Hauck Lithographic printing plate precursors and methods of use
US20120141942A1 (en) 2010-12-03 2012-06-07 Domenico Balbinot Method of preparing lithographic printing plates
US20120141941A1 (en) 2010-12-03 2012-06-07 Mathias Jarek Developing lithographic printing plate precursors in simple manner
US20120141935A1 (en) 2010-12-03 2012-06-07 Bernd Strehmel Developer and its use to prepare lithographic printing plates
US8933132B2 (en) 2011-01-19 2015-01-13 Convergence Pharmaceuticals Limited Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockers
US20120199028A1 (en) 2011-02-08 2012-08-09 Mathias Jarek Preparing lithographic printing plates
JP2014530177A (ja) 2011-09-16 2014-11-17 フオベア・フアルマシユテイカル アニリン誘導体、それらの調製およびそれらの治療適用
US9029063B2 (en) 2011-09-22 2015-05-12 Eastman Kodak Company Negative-working lithographic printing plate precursors
US8632941B2 (en) 2011-09-22 2014-01-21 Eastman Kodak Company Negative-working lithographic printing plate precursors with IR dyes
CN102311355B (zh) * 2011-09-26 2014-02-05 扬州天和药业有限公司 罗本考昔的一种制备方法
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
US8679726B2 (en) 2012-05-29 2014-03-25 Eastman Kodak Company Negative-working lithographic printing plate precursors
US9063423B2 (en) 2013-02-28 2015-06-23 Eastman Kodak Company Lithographic printing plate precursors and use
US9201302B2 (en) 2013-10-03 2015-12-01 Eastman Kodak Company Negative-working lithographic printing plate precursor
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
US11583516B2 (en) 2016-09-07 2023-02-21 Trustees Of Tufts College Dash inhibitors, and uses related thereto
KR20200113036A (ko) 2017-03-14 2020-10-05 세이가가쿠 고교 가부시키가이샤 관절 질환 처치용 조성물 및 그것을 포함하는 키트
CN117427183A (zh) 2017-03-14 2024-01-23 生化学工业株式会社 关节疾病处置用组合物及含有其的试剂盒
KR102069205B1 (ko) * 2017-08-09 2020-01-22 연성정밀화학(주) 라타노프로스틴 부노드의 제조 방법 및 그를 위한 중간체
CN109694330B (zh) * 2017-10-24 2023-10-20 乳源瑶族自治县东阳光生物科技有限公司 一种酸的制备方法
WO2020021077A1 (fr) 2018-07-27 2020-01-30 Krka, D.D., Novo Mesto Procédé de préparation de forme polymorphe de robenacoxib
CN109503399B (zh) * 2018-12-29 2021-12-24 江苏天和制药有限公司 一种罗本考昔的制备方法
CN110437090A (zh) * 2019-07-31 2019-11-12 江苏天和制药有限公司 一种罗本考昔三聚体及其制备方法
CN111807978B (zh) * 2020-07-29 2023-03-14 武汉川泰科技有限公司 一种罗贝考昔的制备方法
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar HYALURONIC ACID-CONJUGATED DIPALMITOYL PHOSPHATIDYL ETHANOLAMINE IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) FOR TREATING OR ALLEVIATING INFLAMMATORY DISEASES
EP4281183A1 (fr) 2022-03-23 2023-11-29 Alivira Animal Health Limited Procédé amélioré de purification de robénacoxib

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558690A (en) 1965-04-08 1971-01-26 Gelgy Chemical Corp Substituted derivatives of 2-anilinophenylacetic acids and a process of preparation
US3895063A (en) 1965-04-08 1975-07-15 Ciba Geigy Corp Substituted Anilino Benzyl Alcohols
GB1166861A (en) 1966-01-15 1969-10-15 Aspro Nicholas Ltd New Diphenylamine Derivatives and Compositions containing them
US3652762A (en) 1970-04-14 1972-03-28 Ciba Geigy Corp Pharmaceutical compositions and methods employing substituted derivatives of 2-anilinophenylacetic acids and esters
US4173577A (en) 1970-09-09 1979-11-06 Ciba-Geigy Corporation Phenylacetohydroxamic acids
ES520813A0 (es) 1983-03-21 1984-05-16 Prodes Sa Procedimiento para la obtencion del ester del acido 2-(2,6-diclorofenil)amino bencenoacetico con acido glicolico.
DE3445011A1 (de) 1983-12-13 1985-06-13 Ciba-Geigy Ag, Basel Neues anilinderivat, verfahren zu seiner herstellung und seine verwendung
IT1256345B (it) 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
ES2132672T3 (es) 1994-06-29 1999-08-16 Novartis Ag Nuevas sales de acido 2-((2,6-diclorofenil)amino)fenil-acetoxiacetico con cationes basicos organicos.
JPH0977664A (ja) 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados

Also Published As

Publication number Publication date
US20040122254A1 (en) 2004-06-24
CA2298033A1 (fr) 1999-03-11
NL300379I2 (nl) 2010-02-01
DK1007505T3 (da) 2003-07-21
HUP0002514A3 (en) 2002-11-28
PT1007505E (pt) 2003-08-29
NL300379I1 (nl) 2009-05-06
HUP0002514A2 (hu) 2000-12-28
SK2472000A3 (en) 2000-09-12
US20020183391A1 (en) 2002-12-05
CY2007020I1 (el) 2012-01-25
CZ2000714A3 (cs) 2000-06-14
KR100637296B1 (ko) 2006-10-23
US7115662B2 (en) 2006-10-03
LU91346I2 (fr) 2007-09-11
PL194480B1 (pl) 2007-06-29
NO2009007I2 (no) 2010-06-07
EP1007505A1 (fr) 2000-06-14
TWI250142B (en) 2006-03-01
HU225774B1 (en) 2007-08-28
CZ298522B6 (cs) 2007-10-24
ATE237580T1 (de) 2003-05-15
WO1999011605A1 (fr) 1999-03-11
LU91540I2 (fr) 2009-05-11
KR20010023344A (ko) 2001-03-26
CY2007020I2 (el) 2012-01-25
AU743371B2 (en) 2002-01-24
CO4960662A1 (es) 2000-09-25
NO326196B1 (no) 2008-10-13
MY127881A (en) 2006-12-29
US6727281B2 (en) 2004-04-27
PE108099A1 (es) 1999-11-18
IL134498A0 (en) 2001-04-30
US20020013369A1 (en) 2002-01-31
CN1140500C (zh) 2004-03-03
ES2197508T3 (es) 2004-01-01
EP1007505B1 (fr) 2003-04-16
ID23953A (id) 2000-06-08
US6291523B1 (en) 2001-09-18
US6310099B1 (en) 2001-10-30
DE122009000013I1 (de) 2009-06-25
NZ502669A (en) 2002-02-01
IL134498A (en) 2009-06-15
AR015157A1 (es) 2001-04-18
BR9812010A (pt) 2000-12-12
DE122007000035I2 (de) 2010-07-01
TR200000447T2 (tr) 2000-07-21
DE69813570D1 (de) 2003-05-22
BR9812010B1 (pt) 2010-12-14
HK1031374A1 (en) 2001-06-15
RU2186762C2 (ru) 2002-08-10
WO1999011605A8 (fr) 2000-03-02
FR09C0011I1 (fr) 2009-04-17
JP2001514244A (ja) 2001-09-11
NO20000943L (no) 2000-02-25
JP3704470B2 (ja) 2005-10-12
DE69813570T2 (de) 2004-02-12
CA2298033C (fr) 2007-10-02
DE122007000035I1 (de) 2007-07-19
CN1268112A (zh) 2000-09-27
US6451858B2 (en) 2002-09-17
PL338357A1 (en) 2000-10-23
AU9534098A (en) 1999-03-22
NO2009007I1 (no) 2009-04-06
NO20000943D0 (no) 2000-02-25
SK283773B6 (sk) 2004-01-08
SI1007505T1 (en) 2003-10-31

Similar Documents

Publication Publication Date Title
CH0944937H2 (fr)
ITMI971410A0 (fr)
BR9700653A (fr)
BR9701757A (fr)
ITRM970103V0 (fr)
CN3057976S (fr)
BY4238C1 (fr)
BY4349C1 (fr)
CN3053170S (fr)
CN3053500S (fr)
CN3053525S (fr)
CN3054099S (fr)
CN3054162S (fr)
CN3054556S (fr)
CN3054902S (fr)
CN3055123S (fr)
CN3055179S (fr)
CN3055389S (fr)
CN3055471S (fr)
CN3055519S (fr)
CN3055603S (fr)
CN3055713S (fr)
CN3056209S (fr)
CN3056251S (fr)
CN3056276S (fr)